<DOC>
	<DOC>NCT01616849</DOC>
	<brief_summary>This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.</brief_summary>
	<brief_title>Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic diagnosis of nasopharyngeal carcinoma Distance metastasis at least 6 months after radical treatment Not suitable for local treatment, e.g. surgery, TACE At least one measurable lesion Estimate survival ＞3months Range from 18～70 years old PS 0~1 WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L ALT or AST ＜ 2.5×ULN、bilirubin ＜ 1.5×ULN 0Serum creatinine ＜ 1.5×ULN Central nervous system metastases Suitable for local treatment Second malignancy within 5 years Precious therapy with an investigational agent Uncontrolled seizure disorder or other serious neurologic disease ≥ Grade Ш allergic reaction to any drug including in this study Clinically significant cardiac or respiratory disease Creatinine clearance &lt; 30ml/min Drug or alcohol addition Do not have full capacity for civil acts Severe complication, active infection Concurrent immunotherapy or hormone therapy for other diseases Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>